NCT05107778 - Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

November 14, 2023

Study Completion Date

December 14, 2023

Conditions

Hepatitis B, Chronic

Interventions

DRUG

ASC42 10mg

ASC42 10mg orally once daily;

DRUG

ASC42 15mg

ASC42 15mg orally once daily.

DRUG

ih PEG-IFN α-2a

ih PEG-IFN α-2a 180μg subcutaneous injection once a week.

DRUG

Entecavir

Entecavir 0.5 mg orally once daily.

DRUG

Placebo

Placebo orally once daily.

Trial Locations (1)

NanFang Hospital of Southern Medical University, Guangzhou